BACKGROUND: Sleep disturbance is a common clinical complaint of oncology patients and contributes to substantial morbidity. However, because most sleep studies have been cross-sectional, associations between sleep quality and distress in patients with ovarian cancer over time remain unclear. This prospective longitudinal study examined rates of sleep disturbance; contributions of depression, anxiety, and medication use in sleep disturbance; and associations between sleep quality and quality of life (QOL) during the first year after diagnosis among women with ovarian cancer. METHODS: Women with a pelvic mass completed measures of sleep quality, depression, anxiety, and QOL before surgery. Those diagnosed with primary epithelial ovarian, fallopian tube, or peritoneal cancer repeated surveys at 6 months and 1 year after diagnosis. Mixed modeling was used to examine trajectories of psychosocial measures over time, as well as associations between changes in distress and sleep quality. Relationships between changes in sleep and QOL were also examined. RESULTS: The majority of patients reported disturbed global sleep (Pittsburgh Sleep Quality Index > 5) at all 3 time points. Medications for sleep and pain were associated with worse sleep at all time points. Greater increases in depression were associated with increased disturbances in sleep quality over time (P < .04). Worsening sleep was also associated with declines in QOL over time (P < .001). CONCLUSIONS: Sleep disturbance is common and persistent in women with ovarian cancer, and is linked to depressive symptoms and QOL. Pharmacologic treatment does not appear to adequately address this problem. Results highlight the need for ongoing screening and intervention for sleep disturbance in this population.
BACKGROUND:Sleep disturbance is a common clinical complaint of oncology patients and contributes to substantial morbidity. However, because most sleep studies have been cross-sectional, associations between sleep quality and distress in patients with ovarian cancer over time remain unclear. This prospective longitudinal study examined rates of sleep disturbance; contributions of depression, anxiety, and medication use in sleep disturbance; and associations between sleep quality and quality of life (QOL) during the first year after diagnosis among women with ovarian cancer. METHODS:Women with a pelvic mass completed measures of sleep quality, depression, anxiety, and QOL before surgery. Those diagnosed with primary epithelial ovarian, fallopian tube, or peritoneal cancer repeated surveys at 6 months and 1 year after diagnosis. Mixed modeling was used to examine trajectories of psychosocial measures over time, as well as associations between changes in distress and sleep quality. Relationships between changes in sleep and QOL were also examined. RESULTS: The majority of patients reported disturbed global sleep (Pittsburgh Sleep Quality Index > 5) at all 3 time points. Medications for sleep and pain were associated with worse sleep at all time points. Greater increases in depression were associated with increased disturbances in sleep quality over time (P < .04). Worsening sleep was also associated with declines in QOL over time (P < .001). CONCLUSIONS:Sleep disturbance is common and persistent in women with ovarian cancer, and is linked to depressive symptoms and QOL. Pharmacologic treatment does not appear to adequately address this problem. Results highlight the need for ongoing screening and intervention for sleep disturbance in this population.
Authors: D Bodurka-Bevers; K Basen-Engquist; C L Carmack; M A Fitzgerald; J K Wolf; C de Moor; D M Gershenson Journal: Gynecol Oncol Date: 2000-09 Impact factor: 5.482
Authors: Lauren Clevenger; Andrew Schrepf; Desire Christensen; Koen DeGeest; David Bender; Amina Ahmed; Michael J Goodheart; Frank Penedo; David M Lubaroff; Anil K Sood; Susan K Lutgendorf Journal: Brain Behav Immun Date: 2012-04-21 Impact factor: 7.217
Authors: Karen O Anderson; Carl J Getto; Tito R Mendoza; Stephen N Palmer; Xin Shelley Wang; Cielito C Reyes-Gibby; Charles S Cleeland Journal: J Pain Symptom Manage Date: 2003-04 Impact factor: 3.612
Authors: Barry V Fortner; Edward J Stepanski; Stephanie C Wang; Sarah Kasprowicz; H Heith Durrence Journal: J Pain Symptom Manage Date: 2002-11 Impact factor: 3.612
Authors: Susan K Lutgendorf; Eileen Shinn; Jeanne Carter; Susan Leighton; Keith Baggerly; Michele Guindani; Bryan Fellman; Marianne Matzo; George M Slavich; Marc T Goodman; William Tew; Jenny Lester; Kathleen M Moore; Beth Y Karlan; Douglas A Levine; Anil K Sood Journal: Gynecol Oncol Date: 2017-05-17 Impact factor: 5.482
Authors: Anita R Peoples; Sheila N Garland; Michael L Perlis; Josée Savard; Charles E Heckler; Charles S Kamen; Julie L Ryan; Karen M Mustian; Michelle C Janelsins; Luke J Peppone; Gary R Morrow; Joseph A Roscoe Journal: J Cancer Surviv Date: 2017-01-19 Impact factor: 4.442
Authors: Lauren Clevenger; Andrew Schrepf; Desire Christensen; Koen DeGeest; David Bender; Amina Ahmed; Michael J Goodheart; Frank Penedo; David M Lubaroff; Anil K Sood; Susan K Lutgendorf Journal: Brain Behav Immun Date: 2012-04-21 Impact factor: 7.217
Authors: Thomas Hyphantis; Panagiota Goulia; Ioannis Zerdes; Solomis Solomou; Elias Andreoulakis; André F Carvalho; Nicholas Pavlidis Journal: Dig Dis Sci Date: 2015-08-20 Impact factor: 3.199
Authors: Bryan J Evans; Kristin M Phillips; Brian D Gonzalez; Sachin Apte; Brent J Small; Paul B Jacobsen; Heather S L Jim Journal: J Psychosoc Oncol Date: 2016-01-15